Olodaterol shows anti‐fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis

摘要

Background and PurposeIdiopathic pulmonary fibrosis (IPF) is a fatal respiratory disease characterized by excessive fibroblast activation ultimately leading to scarring of the lungs. Although, the activation of β2‐adrenoceptors (β2‐AR) has been shown to inhibit pro‐fibrotic events primarily in cell lines, the role of β2‐adrenoceptor agonists has not yet been fully characterized. The aim of our study was to explore the anti‐fibrotic activity of the long‐acting β2‐adrenoceptor agonist olodaterol in primary human lung fibroblasts (HLF) and in murine models of pulmonary fibrosis.